122 related articles for article (PubMed ID: 17062678)
1. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
Zhang X; Shu XO; Cai Q; Ruan Z; Gao YT; Zheng W
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6037-42. PubMed ID: 17062678
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
3. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.
Yagmurdur MC; Atac FB; Tutar NU; Verdi H; Isiklar I; Ozdemir BH; Ozbek N; Karakayali H; Haberal M
Int Surg; 2008; 93(3):163-8. PubMed ID: 18828272
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
Palmirotta R; Ferroni P; Savonarola A; Martini F; Ciatti F; Laudisi A; Sini V; Del Monte G; Guadagni F; Roselli M
Thromb Res; 2009 Sep; 124(4):403-8. PubMed ID: 19351570
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
Liu SQ; Xue YM; Yang GC; He FY; Zhao XS
Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
[TBL] [Abstract][Full Text] [Related]
10. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
11. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
12. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients.
Corsetti JP; Ryan D; Moss AJ; Rainwater DL; Zareba W; Sparks CE
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):548-54. PubMed ID: 18096824
[TBL] [Abstract][Full Text] [Related]
14. Markers of the uPA system and common prognostic factors in breast cancer.
Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
[TBL] [Abstract][Full Text] [Related]
15. Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferase reporter vector.
Ding Z; Pan JQ
Ann Hematol; 2005 Mar; 84(3):183-7. PubMed ID: 15309528
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility.
Hizawa N; Maeda Y; Konno S; Fukui Y; Takahashi D; Nishimura M
Clin Exp Allergy; 2006 Jul; 36(7):872-6. PubMed ID: 16839401
[TBL] [Abstract][Full Text] [Related]
18. The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS.
Tsangaris I; Tsantes A; Bonovas S; Lignos M; Kopterides P; Gialeraki A; Rapti E; Orfanos S; Dimopoulou I; Travlou A; Armaganidis A
Thromb Res; 2009 Apr; 123(6):832-6. PubMed ID: 18804848
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
20. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
